Verici Dx plc announced the appointment of David Schultenover as Vice President of Quality and Regulatory with immediate effect to project manage this key objective for 2021. David Schultenover, who is an experienced pharmaceutical and medical device quality control & quality assurance management professional with proven success as a consultant and staff member in the scientific, medical, and manufacturing industries, will be responsible for the delivery of Clinical Laboratory Improvement Amendments (CLIA) laboratory approvals. David joins Verici Dx from Thermo Fisher Scientific, where, as Senior Director of Regulatory, Quality and Compliance, he was responsible for 154 people covering regulatory affairs, Quality Assurance and Quality Control. Prior to that he was Quality Assurance Director at MiraVista Diagnostics.